Apyx Medical Inc (APYX)vsNovartis AG ADR (NVS)
APYX
Apyx Medical Inc
$3.46
-5.72%
HEALTHCARE · Cap: $144.73M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 106966% more annual revenue ($56.58B vs $52.84M). NVS leads profitability with a 23.9% profit margin vs -21.2%. APYX appears more attractively valued with a PEG of 0.59. NVS earns a higher WallStSmart Score of 51/100 (C-).
APYX
Hold40
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.7%
Fair Value
$7.09
Current Price
$3.46
$3.63 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.7% year-over-year
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 9.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.1%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : APYX
The strongest argument for APYX centers on Revenue Growth, PEG Ratio. Revenue growth of 34.7% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : APYX
The primary concerns for APYX are Price/Book, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
APYX profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
APYX carries more volatility with a beta of 1.54 — expect wider price swings.
APYX is growing revenue faster at 34.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 40/100), backed by strong 23.9% margins. APYX offers better value entry with a 44.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apyx Medical Inc
HEALTHCARE · MEDICAL DEVICES · USA
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?